3-(4-bromophenyl)-3-(2-dimethylaminoethyl)isochroman-1-one | 1236376-33-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 3-(4-bromophenyl)-3-(2-dimethylaminoethyl)isochroman-1-one
• 英文别名: 3-(4-bromophenyl)-3-[2-(dimethylamino)ethyl]-4H-isochromen-1-one
• CAS: 1236376-33-2
• 化学式: C₁₉H₂₀BrNO₂
• 分子量: 374.277
• InChiKey: HGKMSJPGZIMPFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-bromophenyl)-3-(2-dimethylaminoethyl)isochroman-1-one 在 盐酸 作用下， 以 甲醇 、 乙醚 为溶剂， 生成 3-(4-bromophenyl)-3-(2-dimethylaminoethyl)isochroman-1-one hydrochloride
  参考文献：
  名称：

  Optimization of isochromanone based urotensin II receptor agonists

  摘要：

  A series of novel isochromanone based urotensin II receptor agonists have been synthesized and evaluated for their activity using a functional cell based assay (R-SAT). Several potent and efficacious derivatives were identified with 3-(3,4-dichlorophenyl)-6,7-dimethyl-3-(2-dimethylaminoethyl) isochroman-1-one (28) being the most potent compound showing an EC50-value of 51 nM, thereby being the most potent compound so far within the isochromanone series. In addition, two other heterocyclic systems (isochromanes and tetrahydroisoquinolinones) were investigated and these derivatives were found to be both potent and efficacious. The activity of the isochromane derivatives implies that the carbonyl group of the isochromanone is not necessary for activity. Furthermore it was found that the geometry of the heterocycles was more important for receptor interaction than the composition of the heteroatoms present. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.04.041
• 作为产物：
  描述：

  N-甲基邻甲苯酰胺 、 3-(二甲基氨基)-4'-溴苯丙酮 在 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以42%的产率得到3-(4-bromophenyl)-3-(2-dimethylaminoethyl)isochroman-1-one
  参考文献：
  名称：

  Optimization of isochromanone based urotensin II receptor agonists

  摘要：

  A series of novel isochromanone based urotensin II receptor agonists have been synthesized and evaluated for their activity using a functional cell based assay (R-SAT). Several potent and efficacious derivatives were identified with 3-(3,4-dichlorophenyl)-6,7-dimethyl-3-(2-dimethylaminoethyl) isochroman-1-one (28) being the most potent compound showing an EC50-value of 51 nM, thereby being the most potent compound so far within the isochromanone series. In addition, two other heterocyclic systems (isochromanes and tetrahydroisoquinolinones) were investigated and these derivatives were found to be both potent and efficacious. The activity of the isochromane derivatives implies that the carbonyl group of the isochromanone is not necessary for activity. Furthermore it was found that the geometry of the heterocycles was more important for receptor interaction than the composition of the heteroatoms present. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.04.041

文献信息

• Optimization of isochromanone based urotensin II receptor agonists
  作者：Fredrik Lehmann、Erika A. Currier、Roger Olsson、Jian-Nong Ma、Ethan S. Burstein、Uli Hacksell、Kristina Luthman

  DOI：10.1016/j.bmc.2010.04.041

  日期：2010.7

  A series of novel isochromanone based urotensin II receptor agonists have been synthesized and evaluated for their activity using a functional cell based assay (R-SAT). Several potent and efficacious derivatives were identified with 3-(3,4-dichlorophenyl)-6,7-dimethyl-3-(2-dimethylaminoethyl) isochroman-1-one (28) being the most potent compound showing an EC50-value of 51 nM, thereby being the most potent compound so far within the isochromanone series. In addition, two other heterocyclic systems (isochromanes and tetrahydroisoquinolinones) were investigated and these derivatives were found to be both potent and efficacious. The activity of the isochromane derivatives implies that the carbonyl group of the isochromanone is not necessary for activity. Furthermore it was found that the geometry of the heterocycles was more important for receptor interaction than the composition of the heteroatoms present. (C) 2010 Elsevier Ltd. All rights reserved.